A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers : positive impacts of the Lu177- PSMA treatment in the advanced stage of prostate cancer

Thumbnail Image

Files

Vyas, M. (2019).pdf (1.56 MB)

Supplementary material

Other Title

Authors

Vyas, Madhusudan
Fagan, Jessica
Shaikh, Shamim

Author ORCID Profiles (clickable)

Degree

Grantor

Date

2019-08-31

Supervisors

Type

Conference Contribution - Oral Presentation

Ngā Upoko Tukutuku (Māori subject headings)

Keyword

cancer patients
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
New Zealand
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC

ANZSRC Field of Research Code (2020)

1112 Oncology and Carcinogenesis
110313 Nuclear Medicine

Citation

Vyas, M., Fagan, J., & Shaikh, S. (2019, September). A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers: Positive impacts of the Lu177- PSMA Treatment in the advanced stage of Prostate cancer. Paper presented at the NZIMRT/ANZSNM-2019, Rotorua, New Zealand.

Abstract

Objective To evaluate the impact/effects of Lutetium-177-PSMA based treatment in improving the quality of life in patients with advanced stage of prostate cancer (mCRPC) Methodology Epidemiology (Global data) Epidemiology (NZ Data) Diagnosis and staging Treatment plan Metastatic disease(mCRPC) Metastatic disease(mCRPC) Metastatic disease(mCRPC) treatment algorithm Metastatic disease(mCRPC) treatment review of literature Prostate specific membrane antigen (PSMA) and mCRPC Various Prostate specific membrane antigen (PSMA) ligands and radionuclides suitable for labelling Lu-177 PSMA based Metastatic disease(mCRPC) treatment review of literature Lu-177-PSMA Treatment outcomes Lu-177 based therapeutic radiopharmaceuticals based treatment outcomes Physiological outcomes of the treatment, at our clinical site QoL, Pain and PSA levels; relative comparison PSA response and QoLoutcomes to Lu-177-PSMA, at our clinical site Third line treatment v/s Lu-177-PSMA Third line treatment v/s Lu-177-PSMA;Feedback from patients Conclusion Reference

Publisher

Permanent link

https://hdl.handle.net/10652/4714

Link to ePress publication

DOI

Copyright holder

Authors

Copyright notice

All rights reserved

Copyright license

Available online at

This item appears in:

Health Sciences Conference Papers